Biomarin prepares for European approval of Ascendis competitor

US firm Biomarin has upgraded its financial expectations based on Q2, and is preparing a new drug that will challenge the existing market.
The EMA HQ in Amsterdam. | Photo: Rob Acket/EMA
The EMA HQ in Amsterdam. | Photo: Rob Acket/EMA
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY CATHERINE BRETT AND CHRISTOFFER ØSTERGAARD

US biotech firm Biomarin ended the second quarter with a revenue growth of 17 percent compared to the same period last year. The result was USD 501.7m.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading